Ritonavir

Key Product Details

Product Description

Ritonavir is a HIV-1 and HIV-2 protease inhibitor (EC₅₀ values are 0.022-0.13 and 0.16 μM, respectively). Blocks the metabolism of protease inhibitors by liver enzyme cytochrome P450-3A4 (CYP3A4). Orally bioavailable. When used in combination with lopinavir, improves outcome in an animal model of MERS-CoV infection.

Product Specifications for Ritonavir

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Ritonavir

The following data is based on the product molecular weight 720.94.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	6.94 mL	34.68 mL	69.35 mL
1 mM	1.39 mL	6.94 mL	13.87 mL
2 mM	0.69 mL	3.47 mL	6.94 mL
10 mM	0.14 mL	0.69 mL	1.39 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 6 publications citing the usage of this product.

• Chan Treatment with Lopinavir/Ritonavir or Interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J.Infect.Dis. 2015 PMID: 26198719
• Kempf Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J.Med.Chem. 1998 PMID: 9484509
• Zeldin Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J.Antimicrob.Chemother. 2004 PMID: 14657084
• Kempf ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc.Natl.Acad.Sci.U.S.A. 1995 PMID: 7708670

Product Documents for Ritonavir